Technical Analysis for XENE - Xenon Pharmaceuticals Inc.

Grade Last Price % Change Price Change
F 39.21 -0.98% -0.39
XENE closed down 0.98 percent on Friday, February 7, 2025, on 87 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Feb 26
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
200 DMA Resistance Bearish -0.98%
50 DMA Resistance Bearish -0.98%
Fell Below 20 DMA Bearish -0.98%
MACD Bearish Centerline Cross Bearish -0.98%
Bollinger Band Squeeze Range Contraction -0.98%
Multiple of Ten Bearish Other -0.98%
200 DMA Resistance Bearish -2.34%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 15 hours ago
60 Minute Opening Range Breakdown about 17 hours ago
Down 1% about 19 hours ago
20 DMA Resistance about 19 hours ago
Rose Above 20 DMA about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xenon Pharmaceuticals Inc. Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pain Organic Compounds Chemical Compounds Gene Therapy Cardiovascular Disease Osteoarthritis Analgesics Knee Acne Pharmaceutical Industries Lipoprotein Neuropathic Pain Treatment Of Osteoarthritis Teva Pharmaceutical Industries Treatment Of Cardiovascular Disease Alipogene Tiparvovec Erythromelalgia Glybera Lipase Lipoprotein Lipase Deficiency Postherpetic Neuralgia

Is XENE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Comments

Indicators

Indicator Value
52 Week High 50.99
52 Week Low 35.53
Average Volume 368,749
200-Day Moving Average 40.36
50-Day Moving Average 40.25
20-Day Moving Average 39.60
10-Day Moving Average 39.92
Average True Range 1.28
RSI (14) 45.05
ADX 11.04
+DI 20.46
-DI 19.70
Chandelier Exit (Long, 3 ATRs) 37.91
Chandelier Exit (Short, 3 ATRs) 40.73
Upper Bollinger Bands 40.84
Lower Bollinger Band 38.35
Percent B (%b) 0.35
BandWidth 6.30
MACD Line -0.07
MACD Signal Line -0.07
MACD Histogram 0.0066
Fundamentals Value
Market Cap 2.99 Billion
Num Shares 76.2 Million
EPS -2.73
Price-to-Earnings (P/E) Ratio -14.36
Price-to-Sales 181.44
Price-to-Book 3.68
PEG Ratio -0.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 40.38
Resistance 3 (R3) 40.40 40.04 40.19
Resistance 2 (R2) 40.04 39.74 40.03 40.12
Resistance 1 (R1) 39.62 39.55 39.44 39.60 40.05
Pivot Point 39.26 39.26 39.17 39.25 39.26
Support 1 (S1) 38.84 38.96 38.66 38.82 38.37
Support 2 (S2) 38.48 38.77 38.47 38.30
Support 3 (S3) 38.06 38.48 38.24
Support 4 (S4) 38.04